PYXS PYXIS ONCOLOGY INC

Pyxis Oncology to Participate in September Investor and Industry Conferences

Pyxis Oncology to Participate in September Investor and Industry Conferences

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences.

Investor Conferences

  • 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET – Fireside chat and investor one-on-one meetings.



  • H.C. Wainwright 27th Annual Global Investment Conference, New York, NY, Monday, September 8, 10:30 a.m. ET – Fireside chat and investor one-on-one meetings.

Industry Conference

  • 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit, Boston, MA, Tuesday, September 9, 3:20 p.m. ET – Company presentation (not webcast).

Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, .

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.

To learn more, visit  or follow us on  and .

Pyxis Oncology Contact

Jitu Wadhane

Principal Financial and Accounting Officer

Media

Molly Devlin

Real Chemistry



EN
21/08/2025

Underlying

PYXSPYXIS ONCOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PYXIS ONCOLOGY INC

 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transi...

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company’s strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology’s Board of Directors since the Company’s IPO and a highly experienced biotechnology executive with a proven track record in adv...

February 3, 2026 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvota...

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma 46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combi...

December 18, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Participate in Upcoming Investor Conferences

Pyxis Oncology to Participate in Upcoming Investor Conferences BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. – Fireside chat.Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. – Fireside chat. Live webcasts and r...

November 3, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025...

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results -  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 -  Clinical update to focus on preliminary data from Phase 1 monotherapy dose expansion study of MICVO in 2L/3L R/M HNSCC patients, including from both post platinum & PD-1 and post EGFR & PD-1 arms, and preliminary data from Phase 1/2 combination dose escalation study of MICVO and ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Present Translational Data and Key Biology Findings ...

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell death Findings demonstrate MICVO’s effects on tumor microenvironment remodeling and immune activation Translational data to be presented in two posters at ESMO 2025 and six posters at AACR-NCI-EORTC ...

October 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch